8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Mar 23, 2026·SEC
Arcus Biosciences, Inc.(RCUS)Earnings, Financials & Key Ratios
RCUS•NYSE
$26.06
$2.62B mkt cap·Price updated May 6, 2026
AboutArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.Show more
- Revenue$247M-4.3%
- EBITDA-$376M-17.5%
- Net Income-$353M-24.7%
- EPS (Diluted)-3.29-4.8%
- Gross Margin95.95%-4.0%
- EBITDA Margin-152.23%-22.7%
- Operating Margin-156.28%-22.2%
- Net Margin-142.91%-30.3%
- ROE-63.26%-5.8%
- ROIC-64.12%+4.0%
- Debt/Equity0.16+26.8%
- Interest Coverage-43.13+38.2%
RCUS Key Insights
Arcus Biosciences, Inc. (RCUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 90 (top 10%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 25.9%
✗Weaknesses
- ✗Profits declining 23.5% over 5 years
- ✗Weak Piotroski F-Score: 0/9
- ✗Negative free cash flow
- ✗Shares diluted 19.2% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RCUS Price & Volume
Arcus Biosciences, Inc. (RCUS) stock price & volume — 10-year historical chart
Loading chart...
RCUS Growth Metrics
Arcus Biosciences, Inc. (RCUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years25.93%
3 Years30.16%
TTM67.38%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM5.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM24.6%
Return on Capital
10 Years-27.85%
5 Years-25.52%
3 Years-37.02%
Last Year-42.14%
RCUS Recent Earnings
Arcus Biosciences, Inc. (RCUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 25, 2026EPS
$0.89
Est $1.11
+19.8%
Revenue
$33M
Est $36M
-7.6%
Q4 2025
Oct 28, 2025EPS
$1.27
Est $1.33
+4.5%
Revenue
$26M
Est $25M
+4.3%
Q3 2025
Aug 6, 2025EPS
$0.08
Est $1.14
+93.4%
Revenue
$160M
Est $32M
+392.6%
Q2 2025
May 6, 2025EPS
$1.14
Est $1.02
-11.8%
Revenue
$28M
Est $37M
-25.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.89vs $1.11+19.8% | $33Mvs $36M-7.6% |
| Q4 2025 | Oct 28, 2025 | $1.27vs $1.33+4.5% | $26Mvs $25M+4.3% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $1.14+93.4% | $160Mvs $32M+392.6% |
| Q2 2025 | May 6, 2025 | $1.14vs $1.02-11.8% | $28Mvs $37M-25.0% |
Based on last 12 quarters of dataView full earnings history →
RCUS Peer Comparison
Arcus Biosciences, Inc. (RCUS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AGEN | 147.29M | 4.17 | -1226.47 | 10.37% | 0.1% | |||
 EXEL | 11.28B | 44.42 | 15.98 | 6.98% | 35.08% | 40.21% | 7.48% | 0.08 |
 HALO | 7.76B | 65.87 | 25.73 | 37.55% | 22.69% | 6.49% | 8.31% | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 TGTX | 5.7B | 36.10 | 240.67 | 40.8% | 13.31% | 21.87% | 1.14 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 NKTR | 1.65B | 84.16 | -8.65 | -43.89% | -192.87% | -356.81% | 0.95 | |
 INCY | 19.47B | 97.47 | 15.21 | 21.22% | 26.71% | 29.31% | 6.96% | 0.01 |
Compare RCUS vs Peers
Arcus Biosciences, Inc. (RCUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RCUS Income Statement
Arcus Biosciences, Inc. (RCUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.41M | 8.35M | 15M | 78M | 383M | 112M | 117M | 258M | 247M | 236M |
| Revenue Growth % | - | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -4.26% | 67.38% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10M | 5M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | 4.05% | - |
| Gross Profit | 1.41M▲ 0% | 8.35M▲ 491.2% | 15M▲ 79.6% | 78M▲ 420.0% | 383M▲ 391.0% | 112M▼ 70.8% | 117M▲ 4.5% | 258M▲ 120.5% | 237M▼ 8.1% | 214M▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 95.95% | 90.68% |
| Gross Profit Growth % | 207.53% | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -8.14% | - |
| Operating Expenses | 54.85M | 63.21M | 103.71M | 202M | 329M | 392M | 457M | 588M | 623M | 629M |
| OpEx % of Revenue | 3882.09% | 756.76% | 691.39% | 258.97% | 85.9% | 350% | 390.6% | 227.91% | 252.23% | - |
| Selling, General & Admin | 7.64M | 13.57M | 25.23M | 43M | 72M | 104M | 117M | 120M | 110M | 111M |
| SG&A % of Revenue | 540.41% | 162.41% | 168.19% | 55.13% | 18.8% | 92.86% | 100% | 46.51% | 44.53% | - |
| Research & Development | 47.22M | 49.65M | 78.48M | 159M | 257M | 288M | 340M | 448M | 523M | 523M |
| R&D % of Revenue | 3341.68% | 594.35% | 523.21% | 203.85% | 67.1% | 257.14% | 290.6% | 173.64% | 211.74% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20M | -10M | -2M |
| Operating Income | -53.44M▲ 0% | -54.86M▼ 2.7% | -88.71M▼ 61.7% | -124M▼ 39.8% | 54M▲ 143.5% | -280M▼ 618.5% | -340M▼ 21.4% | -330M▲ 2.9% | -386M▼ 17.0% | -398M▲ 0% |
| Operating Margin % | -3782.09% | -656.76% | -591.39% | -158.97% | 14.1% | -250% | -290.6% | -127.91% | -156.28% | -168.64% |
| Operating Income Growth % | -193.92% | -2.65% | -61.7% | -39.78% | 143.55% | -618.52% | -21.43% | 2.94% | -16.97% | - |
| EBITDA | -50.83M | -51.2M | -85.13M | -121M | 58M | -274M | -332M | -320M | -376M | -391M |
| EBITDA Margin % | -3597.24% | -612.89% | -567.54% | -155.13% | 15.14% | -244.64% | -283.76% | -124.03% | -152.23% | -165.68% |
| EBITDA Growth % | -201.33% | -0.72% | -66.29% | -42.13% | 147.93% | -572.41% | -21.17% | 3.61% | -17.5% | 8.22% |
| D&A (Non-Cash Add-back) | 2.61M | 3.66M | 3.58M | 3M | 4M | 6M | 8M | 10M | 10M | 7M |
| EBIT | -53.44M | -54.86M | -84.71M | -123M | 55M | -264M | -299M | -279M | -345M | -214M |
| Net Interest Income | 775K | 4.92M | 5.2M | 1M | 1M | 14M | 39M | 48M | -8M | 32M |
| Interest Income | 775K | 4.92M | 5.2M | 1M | 1M | 16M | 41M | 52M | 0 | 51M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 2M | 2M | 4M | 8M | 16M |
| Other Income/Expense | 359K | 5.26M | 4M | 1M | 1M | 14M | 39M | 47M | 33M | 29M |
| Pretax Income | -53.08M▲ 0% | -49.59M▲ 6.6% | -84.71M▼ 70.8% | -123M▼ 45.2% | 55M▲ 144.7% | -266M▼ 583.6% | -301M▼ 13.2% | -283M▲ 6.0% | -353M▼ 24.7% | -369M▲ 0% |
| Pretax Margin % | -3756.69% | -593.73% | -564.73% | -157.69% | 14.36% | -237.5% | -257.26% | -109.69% | -142.91% | -156.36% |
| Income Tax | 0 | 0 | 0 | 0 | 2M | 1M | 6M | 1M | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 3.64% | -0.38% | -1.99% | -0.35% | 0% | 0% |
| Net Income | -53.08M▲ 0% | -49.59M▲ 6.6% | -84.71M▼ 70.8% | -123M▼ 45.2% | 53M▲ 143.1% | -267M▼ 603.8% | -307M▼ 15.0% | -283M▲ 7.8% | -353M▼ 24.7% | -369M▲ 0% |
| Net Margin % | -3756.69% | -593.73% | -564.73% | -157.69% | 13.84% | -238.39% | -262.39% | -109.69% | -142.91% | -156.36% |
| Net Income Growth % | -195.39% | 6.57% | -70.81% | -45.2% | 143.09% | -603.77% | -14.98% | 7.82% | -24.73% | 5.63% |
| Net Income (Continuing) | -53.08M | -49.59M | -84.71M | -123M | 53M | -267M | -307M | -284M | -353M | -369M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.16▲ 0% | -1.43▲ 33.8% | -1.73▼ 21.0% | -2.13▼ 23.1% | 0.71▲ 133.3% | -3.71▼ 622.5% | -4.15▼ 11.9% | -3.14▲ 24.3% | -3.29▼ 4.8% | -2.94▲ 0% |
| EPS Growth % | -195.89% | 33.8% | -20.98% | -23.12% | 133.33% | -622.54% | -11.86% | 24.34% | -4.78% | 24.6% |
| EPS (Basic) | -2.16 | -1.43 | -1.73 | -2.13 | 0.76 | -3.71 | -4.15 | -3.14 | -3.29 | - |
| Diluted Shares Outstanding | 24.55M | 34.62M | 43.83M | 54.79M | 73.97M | 72M | 74M | 90.1M | 107.4M | 125.4M |
| Basic Shares Outstanding | 24.55M | 34.62M | 43.83M | 54.79M | 69.35M | 72M | 74M | 90.1M | 107.4M | 125.4M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
RCUS Balance Sheet
Arcus Biosciences, Inc. (RCUS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 176.87M | 258.95M | 192.71M | 735.82M | 1.26B | 1.07B | 831M | 1.02B | 1.01B | 844M |
| Cash & Short-Term Investments | 175.7M | 256.54M | 188.27M | 728.65M | 499.31M | 1.01B | 759M | 978M | 981M | 822M |
| Cash Only | 98.43M | 71.06M | 57.94M | 173.41M | 147.91M | 206M | 127M | 150M | 222M | 201M |
| Short-Term Investments | 77.28M | 185.48M | 130.33M | 555.23M | 351.39M | 803M | 632M | 828M | 759M | 621M |
| Accounts Receivable | 25K | 83K | 132K | 1.7M | 746.82M | 43M | 42M | 25M | 0 | 0 |
| Days Sales Outstanding | 6.46 | 3.63 | 3.21 | 7.95 | 711.72 | 140.13 | 131.03 | 35.37 | - | 13.15 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 251K | 4.47M | 14.72M | 14M | 30M | 13M | 26M | 22M |
| Total Non-Current Assets | 13.62M | 15.98M | 10.4M | 36.48M | 330.15M | 279M | 264M | 134M | 132M | 153M |
| Property, Plant & Equipment | 11.23M | 11.11M | 9.33M | 23.59M | 137.42M | 135M | 51M | 47M | 40M | 38M |
| Fixed Asset Turnover | 0.13x | 0.75x | 1.61x | 3.31x | 2.79x | 0.83x | 2.29x | 5.49x | 6.18x | 5.76x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 682K | 4.38M | 0 | 6.64M | 185M | 134M | 107M | 14M | 0 | 26M |
| Other Non-Current Assets | 1.71M | 487K | 1.07M | 6.25M | 7.73M | 10M | 106M | 73M | 92M | 341M |
| Total Assets | 190.49M▲ 0% | 274.93M▲ 44.3% | 203.11M▼ 26.1% | 772.29M▲ 280.2% | 1.59B▲ 106.1% | 1.34B▼ 15.5% | 1.09B▼ 18.6% | 1.15B▲ 5.0% | 1.14B▼ 1.0% | 997M▲ 0% |
| Asset Turnover | 0.01x | 0.03x | 0.07x | 0.10x | 0.24x | 0.08x | 0.11x | 0.22x | 0.22x | 0.23x |
| Asset Growth % | 73.64% | 44.33% | -26.12% | 280.23% | 106.13% | -15.51% | -18.59% | 5.02% | -0.96% | -46.27% |
| Total Current Liabilities | 12.73M | 16.93M | 22.71M | 121.67M | 166.08M | 193M | 184M | 226M | 231M | 209M |
| Accounts Payable | 3.82M | 3.1M | 4.7M | 15.68M | 10.26M | 20M | 17M | 18M | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | 1.3K |
| Short-Term Debt | 0 | 0 | 0 | 2.87M | 5.1M | 3M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 5M | 6.25M | 7M | 74.57M | 102M | 97M | 91M | 85M | 35M | 192M |
| Other Current Liabilities | 769K | 1.56M | 6.43M | 19.92M | 30.26M | 48M | 39M | 14M | 196M | 175M |
| Current Ratio | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x | 4.36x | 4.36x |
| Quick Ratio | 13.90x | 15.29x | 8.49x | 6.05x | 7.60x | 5.52x | 4.52x | 4.50x | 4.36x | 4.36x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.28K |
| Total Non-Current Liabilities | 23.89M | 23.05M | 16.56M | 148.32M | 584.36M | 495M | 449M | 439M | 277M | 264M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48M | 99M | 100M |
| Capital Lease Obligations | 0 | 0 | 0 | 15.24M | 116.89M | 117M | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.3M | 6.06M | 4.54M | 10.25M | 5.26M | 23M | 142M | 157M | 178M | 653M |
| Total Liabilities | 36.62M | 39.98M | 39.27M | 269.99M | 750.45M | 688M | 633M | 665M | 508M | 473M |
| Total Debt | 0 | 0 | 0 | 18.11M | 121.99M | 120M | 11M | 60M | 99M | 100M |
| Net Debt | -98.43M | -71.06M | -57.94M | -155.31M | -25.93M | -86M | -116M | -90M | -123M | -101M |
| Debt / Equity | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x | 0.16x | 0.16x |
| Debt / EBITDA | - | - | - | - | 2.10x | - | - | - | - | -0.26x |
| Net Debt / EBITDA | - | - | - | - | -0.45x | - | - | - | - | 0.26x |
| Interest Coverage | - | - | - | - | - | -132.00x | -149.50x | -69.75x | -43.13x | -13.38x |
| Total Equity | 153.87M▲ 0% | 234.94M▲ 52.7% | 163.84M▼ 30.3% | 502.3M▲ 206.6% | 841.45M▲ 67.5% | 657M▼ 21.9% | 462M▼ 29.7% | 485M▲ 5.0% | 631M▲ 30.1% | 524M▲ 0% |
| Equity Growth % | 54.7% | 52.69% | -30.26% | 206.58% | 67.52% | -21.92% | -29.68% | 4.98% | 30.1% | -7.59% |
| Book Value per Share | 6.27 | 6.79 | 3.74 | 9.17 | 11.38 | 9.13 | 6.24 | 5.38 | 5.88 | 4.18 |
| Total Shareholders' Equity | 153.87M | 234.94M | 163.84M | 502.3M | 841.45M | 657M | 462M | 485M | 631M | 524M |
| Common Stock | 3K | 4K | 4K | 6K | 7K | 1.21B | 1.31B | 1.62B | 2.12B | 2.14B |
| Retained Earnings | -73.23M | -122.83M | -205.33M | -328.18M | -275.35M | -542M | -849M | -1.13B | -1.49B | -1.61B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -42K | -107K | 64K | 44K | -1.26M | -7M | 0 | 0 | 0 | -1M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCUS Cash Flow Statement
Arcus Biosciences, Inc. (RCUS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -25.06M | -43M | -73.46M | 111.17M | -256.17M | 438M | -306M | -170M | -482M | -482M |
| Operating CF Margin % | -1773.46% | -514.74% | -489.75% | 142.53% | -66.89% | 391.07% | -261.54% | -65.89% | -195.14% | - |
| Operating CF Growth % | -93.6% | -71.58% | -70.86% | 251.33% | -330.43% | 270.98% | -169.86% | 44.44% | -183.53% | -539.11% |
| Net Income | -53.08M | -49.59M | -84.71M | -122.86M | 52.83M | -267M | -307M | -283M | -353M | -369M |
| Depreciation & Amortization | 2.61M | 3.66M | 3.58M | 4.19M | 3.84M | 14M | 8M | 10M | 10M | 9M |
| Stock-Based Compensation | 495K | 3.87M | 8.98M | 22M | 55M | 0 | 73M | 76M | 60M | 63M |
| Deferred Taxes | 416K | -2.1M | 0 | 0 | 4.77M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -98K | -177K | -1.44M | -46K | 3.47M | 68M | -9M | 5M | -5M | -34M |
| Working Capital Changes | 24.6M | 1.33M | 125K | 208.06M | -375.62M | 623M | -71M | 22M | -194M | -157M |
| Change in Receivables | 380K | -58K | -49K | -917K | -17.05M | 704M | 15M | 28M | 9M | 4M |
| Change in Inventory | 0 | 0 | 0 | 21.32M | 14.09M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -267K | -69K | 1.73M | 9.27M | -4.77M | 8M | -1M | 3M | 24M | 18M |
| Cash from Investing | -49.07M | -113.44M | 59.21M | -434.37M | -3.87M | -413M | 194M | -84M | 66M | 148M |
| Capital Expenditures | -5.51M | -3.74M | -1.93M | -3.06M | -26.08M | -6M | -24M | -6M | -2M | -1M |
| CapEx % of Revenue | 390.23% | 44.81% | 12.83% | 3.92% | 6.81% | 5.36% | 20.51% | 2.33% | 0.81% | - |
| Acquisitions | 0 | 0 | 0 | 431M | -22M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -43.56M | -109.7M | 0 | -431M | 22M | -3M | 0 | 0 | 0 | 0 |
| Cash from Financing | 107.4M | 129.07M | 1.12M | 438.68M | 237.34M | 33M | 33M | 277M | 488M | 349M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 5M | 10M | 0 | 47M | 49M | 49M |
| Equity Issued (Net) | 106.88M | 125.11M | -94K | 434M | 220M | 23M | 25M | 228M | 439M | 297M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -94K | -54K | -6K | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 519K | 3.96M | 1.22M | 4.67M | 12.34M | 0 | 8M | 2M | 0 | 3M |
| Net Change in Cash | 33.27M▲ 0% | -27.36M▼ 182.3% | -13.13M▲ 52.0% | 115.48M▲ 979.7% | -22.7M▼ 119.7% | 58.09M▲ 355.9% | -79M▼ 236.0% | 23M▲ 129.1% | 72M▲ 213.0% | 9M▲ 0% |
| Free Cash Flow | -30.57M▲ 0% | -46.74M▼ 52.9% | -75.39M▼ 61.3% | 108.11M▲ 243.4% | -282.25M▼ 361.1% | 432M▲ 253.1% | -330M▼ 176.4% | -176M▲ 46.7% | -484M▼ 175.0% | -489M▲ 0% |
| FCF Margin % | -2163.69% | -559.55% | -502.58% | 138.61% | -73.69% | 385.71% | -282.05% | -68.22% | -195.95% | -207.2% |
| FCF Growth % | -79.39% | -52.88% | -61.29% | 243.41% | -361.06% | 253.06% | -176.39% | 46.67% | -175% | -61.39% |
| FCF per Share | -1.25 | -1.35 | -1.72 | 1.97 | -3.82 | 6.00 | -4.46 | -1.95 | -4.51 | -4.51 |
| FCF Conversion (FCF/Net Income) | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x | 1.37x | 1.33x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RCUS Key Ratios
Arcus Biosciences, Inc. (RCUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -41.91% | -25.51% | -42.48% | -36.93% | 7.89% | -35.64% | -54.87% | -59.77% | -63.26% | -68.97% |
| Return on Invested Capital (ROIC) | -89.32% | -37.52% | -49.32% | -41.07% | 6.97% | -30.29% | -55.62% | -66.8% | -64.12% | -64.12% |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 95.95% | 90.68% |
| Net Margin | -3756.69% | -593.73% | -564.73% | -157.69% | 13.84% | -238.39% | -262.39% | -109.69% | -142.91% | -156.36% |
| Debt / Equity | - | - | - | 0.04x | 0.14x | 0.18x | 0.02x | 0.12x | 0.16x | 0.16x |
| Interest Coverage | - | - | - | - | - | -132.00x | -149.50x | -69.75x | -43.13x | -13.38x |
| FCF Conversion | 0.47x | 0.87x | 0.87x | -0.90x | -4.83x | -1.64x | 1.00x | 0.60x | 1.37x | 1.33x |
| Revenue Growth | - | 491.15% | 79.58% | 420% | 391.03% | -70.76% | 4.46% | 120.51% | -4.26% | 67.38% |
RCUS SEC Filings & Documents
Arcus Biosciences, Inc. (RCUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
RCUS Frequently Asked Questions
Arcus Biosciences, Inc. (RCUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arcus Biosciences, Inc. (RCUS) reported $236.0M in revenue for fiscal year 2025.
Arcus Biosciences, Inc. (RCUS) saw revenue decline by 4.3% over the past year.
Arcus Biosciences, Inc. (RCUS) reported a net loss of $369.0M for fiscal year 2025.
Dividend & Returns
Arcus Biosciences, Inc. (RCUS) has a return on equity (ROE) of -63.3%. Negative ROE indicates the company is unprofitable.
Arcus Biosciences, Inc. (RCUS) had negative free cash flow of $489.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More RCUS
Arcus Biosciences, Inc. (RCUS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates